Cardiovascular. The cardiovascular evaluation consists of a 3-minute step test. It is performed by stepping up and down on a 12-inch bench at 96 beats per minute for 3 minutes. Pulse is counted for one minute immediately following to determine the score. A passing grade is as follows: STEP TEST RANGE Men Women Acceptable Range all ages 103-119 106-117
Cardiovascular. Targets principally involved in diseases of the heart or of the vascular system, including, without limitation, [**], but excluding Targets of [**]. Oral: Targets principally involved in diseases of the oral cavity, including, without limitation, [**], but excluding Targets of [**].
Cardiovascular. Avoid providing the examinee with extraneous clues that will allow him or her to detect the correct answer without actually knowing it. For example, do not put the same key words or descrip- tive words in both the stem and the correct answer but not in the distractors. Please fill in all the information requested on the other side, and don’t forget to in- clude the copy of your source material. Mail to: IHMM, Attn: Board of Examiners, 0000 Xxxxxxxxx Xxxx., Xxxxx 000
Cardiovascular. Includes Xxxx patch products used in cardiovascular and cardiac patching, such as carotid patch, angioplasty, profundaplasty, AV access graft patching, septal defects, outflow tracts, aneurysm repair and other patch angioplasty.
Cardiovascular. 1. No history or symptomatic form of heart disease or any form requiring therapy.
Cardiovascular. There have been reports of sudden death in children and adolescents who were taking atomoxetine at usual doses with existing structural cardiac abnormalities. Although some serious structural cardiac abnormalities alone carry an increased risk of sudden death, atomoxetine should only be used with caution in children or adolescents with known serious structural cardiac abnormalities and in consultation with a cardiac specialist. Atomoxetine can affect heart rate and blood pressure. Most patients taking atomoxetine experience a modest increase in heart rate (mean <10 bpm) and/or increase in blood pressure (mean <5 mm Hg) that may not be clinically important. MHRA advice in January 2012 states that atomoxetine causes clinically important increases in blood pressure or heart rate, or both, in a small proportion of patients. Atomoxetine should not be used in patients with severe cardiovascular or cerebrovascular disorders. Thorough pretreatment screening and regular monitoring of cardiovascular status is recommended. Specialist cardiac evaluation and advice should be sought if pretreatment findings suggest cardiac disease or history, or if symptoms suggesting cardiac disease are found during treatment. It is recommended that heart rate and blood pressure be measured and recorded on a centile chart before treatment is started and, during treatment, after each adjustment of dose and then at least every 6 months to detect possible clinically important increases. Atomoxetine can cause prolongation of the QT interval and so should be used with caution in patients with congenital or acquired long QT or a family history of QT prolongation. As orthostatic hypotension has also been reported, atomoxetine should be used with caution in any condition that may predispose patients to hypotension or conditions associated with abrupt heart rate or blood pressure changes.
Cardiovascular. Timing Major Milestones with respect to expected results, achievements, deliverables Start of Program • Exchange existing knowledge among groups • Define individual contributions to short and long-term goals Year 1 • Establishment of a vector library for imaging of reporter gene expression in myocardial cells and for induction and monitoring of angiogenesis therapy • Establishment of myocardial ischemia and angiogenesis as a pathobiologic and therapeutic target using animal models mouse using cryoablation and coronary artery ligation • Establishment of molecular imaging techniques which provide readouts specific to angiogenesis itself or to factors mediating angiogenesis • Evaluation of macrophage infiltration and other suitable biologic targets in atherosclerotic plaques Year 2 • Establishment of a molecular imaging toolbox for in vivo identification of various precursors and early biologic changes of myocardial diseases • Molecular Imaging assessment of protease activities of macrophages in atherosclerotic plaques Year 3 • Establishment of different administration methods of labelled stem cells near ischemic cardiac lesion using image-guided intracardiac injection, local intravascular injection, systemic intravascular injection • Evaluation of further specific imaging probes for angiogenesis targets, such as binding agents for receptors stimulated by growth factors (e.g. VEGF) Year 4 • Establishment of molecular imaging approaches for non-invasive monitoring of novel molecular and cellular therapies for cardiovascular disease • Use of stem cell transplantation for preservation and restitution of myocardial and vascular integrity • Evaluation of apoptosis processes, protease activity (such as MMP), autonomic nerve tone and post-synaptic signal transduction in the development of left-ventricular remodelling during chronic ischemia and after myocardial infarction Year 5 • Use of molecular imaging tools for translational research from animal models to clinical application • Use of molecular imaging tools for risk stratification and assessment of therapeutic efficacy in the clinical setting • multi-modality molecular imaging algorithm for accurate idenitification of localization and instability of atherosclerotic plaques, and for determination of individual risk in clinical atherosclerotic disease
Cardiovascular. Irregular heart rhythm from mild to severe.
